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“Novelty and Impact” What’s new? (max. 75 words) 
Hyaluronan (HA) and collagen are highly expressed in pancreatic cancer (PC) stroma. HA and 
collagen accumulation increase tumor interstitial fluid pressure, compromising blood flow and drug 
penetration. High levels of serum HA and propeptide of type III collagen (PRO-C3) were associated 
with short overall survival. Serum HA and PRO-C3 were higher in PC patients than patients with 
benign conditions. The findings warrant further exploration to help clarify links between HA, 
collagen type III, and PC. 
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Abstract 
Hyaluronan (HA) and collagen are highly expressed in pancreatic cancer (PC) stroma. HA and 
collagen accumulation increase tumor interstitial fluid pressure, compromising blood flow and drug 
penetration. The aim of this biomarker study was to determine the clinical utility of serum HA and 
the propeptide of type III collagen (PRO-C3) in patients with PC. A cohort from the Danish BIOPAC 
study (NCT03311776) including patients with histologically confirmed pancreatic ductal 
adenocarcinoma (n=809), ampullary carcinoma (n=44), distal biliary tract cancer (n=31), chronic 
pancreatitis (n=15), intraductal papillary mucinous neoplasm (n=41), duodenal adenoma (n=7), and 
no cancer (n=25). Healthy controls were available for serum HA (n=141) and PRO-C3 (n=8). The 
main outcome was overall survival (OS) of patients with PC in relation to pretreatment serum HA 
and PRO-C3 levels. Patients with PC had higher baseline serum HA and PRO-C3 than healthy 
subjects and patients with benign conditions. Pretreatment serum baseline HA and PRO-C3 in 
patients with PC were associated with poorer survival and PRO-C3 remained prognostic also after 
adjusting for age, performance status, stage, presence of liver and peritoneum metastasis, and CA19-
9. Detection of HA and PRO-C3 may be useful in differentiating between malignant and benign 
pancreatic conditions. Serum HA and PRO-C3 were prognostic for OS in patients with PC.  
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Introduction  
Pancreatic cancer (PC) is one of the most lethal of all major cancers11, 36, 40. Pancreatic ductal 
adenocarcinomas account for 90% of all PC tumors and are highly resistant to all standard treatments 
including chemotherapy, surgery, radiation, and targeted agents, partly due to the multifaceted and 
immunosuppressive tumor microenvironment (TME)4, 6, 39, 49. The prognosis has only improved 
slightly during the last decades, and the overall 5-year survival remains low at 8%36. PC is 
characterized by pronounced inflammation and disperse tumor cells in a dense desmoplastic stroma 
consisting of pancreatic stellate cells (PSCs), carcinoma‐associated fibroblasts, extracellular matrix 
(ECM), endothelial cells, and immune cells. Interaction between stroma and inflammation is 
reported3, 13, 33, 43, 46. Stroma contributes to the hypoxic and avascular microenvironment in both 
primary tumors and metastases10, 49. However, stromal biology and its prognostic impact are still 
under discussion44. Multiple stroma-targeted therapies are under active investigation21, 47. 
Hyaluronic acid (HA), also called hyaluronan, and collagen are major components of the ECM of the 
tumor stroma in PC, and high levels of each are found in both primary tumors and metastatic lesions17, 
20, 49. HA is a glycosaminoglycan that is synthesized at high levels by cancer cells and fibroblasts in 
the TME and promotes tumor growth, angiogenesis, inflammation, immunosuppression as well as 
preserves growth factors and cytokines20, 23, 38, 42.  
The collagen types I, III, and IV are concomitantly overexpressed together with HA in PC49. Collagen 
type IV is the major component of the basement membrane, a specialized ECM that underlies the 
epithelial and endothelial cell layer and plays a major role in tumor cell invasion and angiogenesis. 
Collagen type I and type III are the major components of the stromal ECM and the interstitial matrix. 
They are produced by PSCs within the desmoplastic stroma and promote PC cell adhesion, 
proliferation, migration, and chemo-resistance2, 14, 24, 50, 54. The ECM in the tumor stroma undergoes 
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excessive remodeling. The increased activity of PSC/fibroblasts leads to excessive formation and 
accumulation of interstitial collagens27. HA and collagen accumulation increase tumor solid stress 
and interstitial fluid pressure (IFP), compromising blood vessels, circulation, perfusion, and drug 
penetration8, 25, 29, 37, 42. The prognostic value of HA and collagen deposition in PC tissue has been 
described in a few studies5, 7, 12, 35, 49. HA was hypothesized to be a potential therapeutic target to 
decrease tumor IFP and enhance drug delivery and immune cells’ access into the tumor31, 34, 37. 
Reprogramming of PSC and downregulation of collagen-related signals by the vitamin D receptor 
ligand, calcipotriol, have been shown to improve gemcitabine penetration into the tumor, resulting in 
prolonged survival in PC mouse models35.  
Promising results of targeting of HA in combination with chemotherapy were reported in a 
randomized phase II study, which showed that patients with high HA levels in the tumor 
microenvironment had a largest improvement in progression free survival after addition of 
pegvorhyaluronidase alfa (PEGPH20) to a standard combination of nab-paclitaxel/gemcitabine15. 
Preliminary data based on retrospective analysis of this trial suggested that type III collagen turnover 
measured in serum was able to identify patients that would benefit from the addition of PEGPH2048. 
A phase III study targeting HA is ongoing (NCT02715804). Although HA and collagen expression 
in the TME are considered prognostic biomarkers, there are no/few studies examining serum 
concentrations of HA and type III collagen in patients with PC. Previous studies conducted in other 
malignancies have shown a negative correlation between serum HA and outcome1, 19, 28, 45, 52, 53 and 
serum collagen fragments and outcome7, 18, 22, 51. The aim of this biomarker study was to investigate 
the clinical utility of serum HA and propeptide of type III collagen (PRO-C3) in patients with PC.  
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Materials and Methods 
Patients 
We analyzed pretreatment serum samples from a cohort of patients included in the Danish BIOPAC 
study “Biomarkers in Patients with Pancreatic Cancer” (NCT03311776) from six hospitals in 
Denmark admitted from December 2008 until September 2017. A total of 972 participants, including 
consecutive BIOPAC patients with histologically confirmed PC, ampullary carcinoma (AC), distal 
biliary tract cancer (DBTC), chronic pancreatitis (CP), intraductal papillary mucinous neoplasm 
(IPMN), patients subjected to surgery in whom PC was suspected but not histologically confirmed 
(no pathologic finding), and patients with duodenal adenomas (DA), were studied.  
Serum samples and clinical data from patients were collected prospectively. Retrospective HA and 
PRO-C3 analyses and the clinical data review of electronic medical records were performed 
separately (or independent of each other). Cancer patients were treated with various types of 
chemotherapy according to national guidelines www.gicancer.dk. 
 
Biological samples 
Blood samples were obtained at time of diagnosis and/or before operation if available. Sequential 
samples collected during and after treatment (before 2nd cycle and at the time of first CT scan) were 
available for the group of patients receiving palliative chemotherapy. Samples were processed 
according to the nationally approved standard operation procedures for blood 
(www.herlevhospital.dk/biopac.dk).  
 
Serum HA analysis 
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Pre-treatment and longitudinal serum concentrations of HA were determined by a human HA high-
sensitive solid-phase immunoassay (Quantikine® Immunoassay, R&D Systems, Abingdon, OX, UK) 
in accordance with the manufacturer's instructions. The lower level of detection (LLOD) for HA was 
0.068 ng/mL. The inter-assay coefficient of variation (CV) was ≤7.2% and the intra-assay CV was 
≤4.9%. The molecular weight range of HA detected by the Quanitkine kit was 0.2 – 40.0 ng/mL. The 
median serum HA in 141 healthy blood donors was 41 ng/ml. 
 
Serum PRO-C3 analysis 
Serum PRO-C3 was determined by enzyme-linked immunosorbent assay (ELISA) using a 
monoclonal antibody to detect the N-protease mediated cleavage of the N-terminal propeptide of type 
III collagen (Nordic Bioscience, PRO-C3 assay)26. The LLOD was 4.0 ng/mL. The inter- and intra-
CVs were 11.0% and 4.1%. The molecular weight range of PRO-C3 detected by the Nordic 
Bioscience ELISA kit was 1.1 – 8.5 ng/mL. The median serum PRO-C3 level in eight healthy subjects 
was 7 ng/mL. 
 
ETHICAL ISSUES 
 
The BIOPAC study was approved by the Regional Ethics Committee (VEK ref. KA-20060113) and 
the Danish Data Protection Agency (j.nr. 2006-41-6848). Informed consent for research use was 
obtained from all patients at the enrolling hospitals before prospective serum banking. Serum HA and 
PRO-C3 assessments were not predefined in the protocol but approval was obtained before analysis. 
The responsible investigators ensured that the clinical studies were conducted in agreement with the 
Declaration of Helsinki, version 8. 
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Statistical analysis 
Results are reported in accordance with the REMARK (reporting recommendations for tumor marker 
prognostic study) guidelines32. The objective was to examine the clinical value of serum HA and 
PRO-C3 and the association between baseline and longitudinal serum HA levels and overall survival 
(OS) in the PC patients. Patients were followed from the date of inclusion in the BIOPAC study to 
the end of follow-up (October 24, 2018) or until death from any cause, whichever came first. 
Descriptive statistics were performed to describe patients’ demographics and clinical baseline 
characteristics. Receiver operating characteristic (ROC) analysis was conducted to assess the 
diagnostic values of serum HA. Changes of serum HA and PRO-C3 over time during and after 
systemic treatment and their prognostic value were investigated. Hazard ratios (HRs) adjusted for 
baseline characteristics (age, gender, performance status (PS), stage, history of diabetes, smoking and 
alcohol abuse, serum CA19-9, as well as chemotherapy regimen (gemcitabine, mFOLFIRINOX, 
gemcitabine with nab-paclitaxel, or other), and body mass index (BMI) were estimated with Cox 
proportional-hazard regression. Kaplan–Meier curves were used to illustrate the survival curves in 
patients with PC in relation to measured values of serum HA and PRO-C3 levels, comparing patients 
with the 25% highest values with those with the 75% lowest for each biomarker separately. The 
association between changes in serum HA and PRO-C3 during palliative chemotherapy and OS was 
analyzed in patients in whom sequential (baseline, before 2nd cycle, and at the time of first CT scan) 
data were available. Differences in serum concentration over time from baseline were measured; 
negative values correspond to a decrease in serum HA and PRO-C3. Patients were grouped according 
to change from baseline. Statistical analyses were conducted using the latest version of R (currently 
3.2.4).  
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Data availability  
The data that support the findings of this study are available upon reasonable request from the 
corresponding author. The data are not publicly available due to privacy or ethical restrictions. 
 
Results 
Characteristics of study population 
The study included 972 participants with the following diagnoses: histologically confirmed PC 
(n=809), AC (n=44), DBTC (n=31), CP (n=15), IPMN (n=41), no pathologic finding (n=25), DA 
(n=7 including six patients with high-grade dysplasia and one patient with ungraded dysplasia). 
Clinicopathological data of PC patients are shown in Table 1. The median age was 67 years (range 
37–89 years), and most of the PC patients had PS 0 or 1. The majority of PC patients had advanced 
stage III or IV disease, had normal weight, and were registered as present or earlier smokers. Fifty-
one patients across all stages were never treated with chemotherapy. Of 598 patients who received 
palliative chemotherapy, 404 (67.6%) were treated with gemcitabine, 120 (20.1%) with 
FOLFIRINOX (5-FU, leucovorin, irinotecan, and oxaliplatin), 55 (9.2%) with combination of 
gemcitabine and nab-paclitaxel, and 19 (3.2%) with other combinations. 
 
Pretreatment serum HA and PRO-C3 and clinical characteristics and overall survival 
First, we compared serum HA levels between the study groups (Table 2). The median pretreatment 
HA level was 84 ng/mL (IQR: 48-131). Pretreatment serum HA in patients with cancer including PC, 
AC, DBTC was increased compared to patients with benign conditions or healthy controls. The 
median serum HA level in PC patients was about two‐fold higher than in healthy controls (p<0.001) 
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and was increased compared to patients with benign conditions including CP, IPMN, DA and those 
subjects without pathological findings (p<0.001). No statistically significant difference in HA was 
observed comparing PC with other malignant diseases. We further stratified the PC patients according 
to stage, PS, and presence of liver metastases. Higher serum HA levels were associated with 
metastatic disease, presence of liver metastases, and worse PS (Table 2). Thirty-four percent of 
patients with liver metastases had the highest quartile of serum HA compared to 19% patients without 
liver metastases (p<0.001). Correlation analyses displayed a pairwise positive relation between 
baseline serum HA and PRO-C3, CA19-9 and inflammation markers in patients with PC (Table S1).   
ROC analysis showed that serum HA level had a better potential to discriminate PC patients from 
healthy controls (AUC=0.75, 95% CI 0.72–0.79, Figure 1A) than from patients with benign 
conditions (AUC=0.63, 95% CI 0.57–0.69, Figure 1B).  
We subsequently investigated the clinical value of serum PRO-C3 in the same cohort. The median 
pretreatment PRO-C3 level was 18 ng/mL (IQR: 11-33). Serum PRO-C3 was higher in patients with 
malignant diseases than in those with benign conditions (Table 2). PC patients had higher median 
serum PRO-C3 levels compared to patients with benign conditions (p<0.001). PRO-C3 was positively 
correlated with higher stage and presence of liver metastases (p<0.001). Double as many patients 
with liver metastases had serum PRO-C3 in the highest quartile compared to patients without liver 
metastases (37% versus 18%, p<0.001). PS≥2 was associated with higher serum PRO-C3 values. 
Detection of PRO-C3 performed slightly better as a diagnostic marker than serum HA. ROC analyses 
comparing PC patients with healthy controls and patients with benign conditions yielded an 
AUC=0.87, 95% CI 0.71–1.00 (Figure 1C) and AUC=0.71, 95% CI 0.65–0.76 (Figure 1D). 
Overall survival according to levels of HA and PRO-3C is shown in Figure 2. Univariate analysis 
showed that high baseline serum HA (1.18, 95% CI: 1.13–1.25) and PRO-C3 (1.28, 95%: CI 1.11–
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1.49) were associated with worse prognosis. After allocating patients into stages, a significance 
association was still seen for patients with stage IV (Figure 2). High baseline HA and PRO-C3 levels 
according to types of treatments in 579 patients undergoing palliative chemotherapy were associated 
with short survival (Figures S1). After adjusting factors associated with OS, the HRs for serum HA 
and PRO-C3 were 1.04 (95% CI: 0.97–1.13) and 1.42 (95% CI: 1.14–1.76), respectively (Table 3). 
Further adjustment for inflammatory markers (CRP, IL-6, and YKL-40) changed the HRs to 1.02 
(95% CI: 0.93–1.11) and 1.35 (95% CI: 1.05–1.73) for serum HA and PRO-C3, respectively (Table 
S2 and Supplementary Materials & Methods). Patients with combined 25% highest levels of both 
serum HA and PRO-C3 had the poorest survival (Figure S2). 
 
Prognostic value of changes in serum HA and PRO-C3 over time 
Serum HA levels decreased after the first treatment cycle, with a median difference of −11.50 [IQR, 
−41.98, 12.23] ng/mL, and at the time of first CT evaluation 2 or 3 months after chemotherapy start 
of −34.10 [IQR, −72.95, −5.25] ng/mL compared to the HA level at baseline. In contrast, no decrease 
was observed for longitudinal serum PRO-C3 concentrations: −0.90 [IQR, −3.80, 3.05] and −1.90 
[IQR, −9.30, 4.30] after the first treatment cycle and at the time of first CT evaluation, respectively. 
Changes in HA and PRO-3C were not associated with overall survival (Figure 3). 
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Discussion 
PC remains one of the most aggressive tumors and is known to be highly enriched with ECM in the 
desmoplastic stroma, and HA and collagen are essential components of the ECM. Biomarker 
availability, reliability, and function of the serum levels of HA and N-terminal propeptide of type III 
collagen (PRO-C3) in patients with PC have not been extensively investigated so far. In this study, 
we demonstrated that higher values of serum PRO-C3 and HA at the time of diagnosis are associated 
with an increased mortality. However, serum HA was not associated with OS after adjusting for 
potential confounding factors. This suggests that serum PRO-C3 may serve as prognostic marker in 
patients with PC. In support for this hypothesis, collagen turnover rate needs to be maintained in 
normal tissue homeostasis, and changes in the deposition of collagens result in the tissue fibrosis that 
drives tumorigenesis41. Hence type III collagen synthesis may be a major component of the dense stroma 
(desmoplastic reaction) in the tumor and linked to tumor growth, metastasis, and drug resistance. 
Our findings are in line with reports on the facilitating role of HA and PRO-C3 in the malignant 
behavior of tumor cells and the IFP increase within a tumor, limiting perfusion and compromising 
drug delivery8, 25, 29, 37, 42. Analyses of HA and collagen levels in tumors from patients with PC 
revealed that the survival was worse among patients with high HA and collagen accumulation 
compared to subjects with low HA and collagen expression, suggesting that HA and collagen levels 
in tumors of patients with PC may be predictive of survival5, 49. In contrast, prognostic significant 
relevance was not observed for HA accumulation, found in the majority of the PDAC-resected 
tumors12. Surgical examination of tissues from 114 PC patients identified a particular rearrangement 
of collagen fibers surrounding the tumor as a "biomarker" of early death7. By staining 53 patients’ 
primaries and 57 patients’ metastases, Whatcott et al. found highly fibrotic stroma with high levels 
of HA and collagen type I in both primary tumors and metastases49. PDAC patients with a high 
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expression of HA were more susceptible to therapy targeting HA15. Addition of HA blockade to 
FOLFIRINOX did not shown any benefit in patients unselected for tumor HA status30. Interestingly, 
in our study the more pronounced association with survival of baseline HA according to types of 
treatments in patients undergoing palliative chemotherapy was observed in participants treated with 
gemcitabine and nab-paclitaxel combination (Figures S1). However, due to the small number of 
patients undergoing combination palliative chemotherapy the survival data should be viewed with 
caution. A phase III trial investigating the efficacy of HA blockade in combination with gemcitabine 
and nab-paclitaxel in PDAC is pending (https://clinicaltrials.gov/ct2/show/NCT02715804). Collagen 
type III in PC was found to be linked to fibrosis within ECM and associated with poor prognosis and 
tumorigenesis16, 26. Targeting of collagen compartments in combination with various drugs is under 
extensive investigation. 
We demonstrated that serum HA was increased in PC patients from the BIOPAC cohort compared 
with patients with benign conditions and healthy subjects. Likewise, a significantly higher 
concentration of serum PRO-C3 was observed in PC patients compared to patient with non-malignant 
conditions. Specific protease-generated fragments of collagen were significantly elevated in serum 
from patients with PC compared to controls, and a combination of serum biomarkers reflecting matrix 
metalloproteinase-mediated collagen turnover resulted in complete separation between healthy 
controls and patients with PC50.  
We also demonstrated that high serum HA and PRO-C3 levels at diagnosis were not restricted to 
patients with metastatic PC but were present in all PC patients regardless of stage. However, our study 
suggests an association between higher concentrations of serum HA and PRO-C3 levels and advanced 
stage of disease, many metastatic sites, as well as presence of liver metastases. This is in agreement 
with the suggestion that the increase in matrix components is due to the ECM degradation that occurs 
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during metastasizing9. Furthermore, our findings were compared to patients with other upper 
gastrointestinal cancer diagnoses, including AC and DBTC. No significant difference was observed 
for AC and DBTC compared to patients with PC. Finally, serum HA and PRO-C3 also correlated 
with serum CRP, IL-6, and YKL-40, suggesting mutual interplay between inflammation and stroma.  
While treatment of patients with PC is based on a balance between tolerability and benefit, the 
optimization of non-invasive cost-effective monitoring would be of useful clinical value. Prognosis 
of PC patients often displays a dynamic pattern during systemic treatment. We observed a reduction 
in serum HA but not PRO-C3 levels in longitudinal samples; however, neither a decrease in HA nor 
in PRO-C3 was associated with survival. Pretreatment serum HA and PRO-C3 in patients undergoing 
palliative chemotherapy are more robustly associated with survival than serum HA and PRO-C3 after 
first cycle chemotherapy and at the time of the first evaluation CT scanning. This suggests that 
pretreatment serum HA and PRO-C3 would be more useful in identifying patients at risk of poor 
survival due to primary aggressive biology. However, due to the small number of patients with 
available longitudinal serum samples, natural selection, and the limited number of patients who 
received gemcitabine with nab-paclitaxel or FOLFIRINOX, the survival data according to serum HA 
and PRO-C3 changes should be interpreted with caution. To our knowledge, this is the first large-
scale study to describe serum HA and PRO-C3 in samples derived from population-based consecutive 
patients with PC that can be applied to future research addressing stroma and ECM. 
Several limitations must be noted. First, causal relationships cannot be determined in an observational 
study, and residual confounding is always a concern. However, prospective well-characterized data 
sets with clinico-pathological characteristics and treatment data on consecutive patients across the 
different centers including patients with PC in the BIOPAC study in a well-defined period of time 
reduce residual confounding. Second, staging is based on established routine practice, and it is well 
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known that clinical staging systems are not as clear-cut. However, we demonstrated consistent 
associations between serum HA and PRO-C3 levels with survival across all stages. Third, selection 
bias may affect the generalizability of the results since only around 20% of all registered Danish 
patients with PC are included in the BIOPAC study. Thus, many patients are not referred to systemic 
therapy due to rapid deterioration and die within a short time after diagnosis. Enrolled patients were 
more likely to have better PS, and more likely to receive chemotherapy. Thus, it is possible that the 
relationship between serum HA and PRO-C3 and survival in this subset is not generalizable to all 
patients with PC. Finally, whether serum HA and PRO-C3 values are correlated with HA and PRO-
C3 expression in tumors has not yet been determined.  
In conclusion, we have shown that high serum HA and PRO-C3 levels are associated with increased 
mortality in patients with PC. Moreover, compared to healthy subjects and a group of patients with 
benign conditions, high values of these parameters are measured in patients with malignant lesions, 
including PC, AC, and DBTC. Serum HA and PRO-C3 were associated with PC stage. Our findings 
suggest that serum HA and PRO-C3 levels may have a clinical value and motivate further research 
on serum HA and PRO-C3 as novel, minimally invasive and cost‐effective prognostic and diagnostic 
markers of PC. Our study also supports evidence that encourages ongoing investigation of stroma 
targeting strategies.  
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Table 1. Clinical characteristics of 809 patients with pancreatic cancer.  
Characteristic Number (%) 
Age, median (range) years  
   ˃75 years 
67 (37-89) 
135 (16.7) 
Sex 
   Male 
   Female 
  
440 (54.4) 
369 (45.6) 
ECOG PS 
   0 
   1 
   2+ 
   unknown 
  
283 (35.0) 
346 (42.8) 
103 (12.7) 
77 (9.5) 
Stage 
   I+II 
   III+IV 
  
197 (24.4) 
595 (73.5) 
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   unknown 17 (2.1) 
Diabetes 
   yes 
   no 
  
210 (26.0) 
599 (74.0) 
Smoking  
   yes 
   no 
   unknown 
  
483 (59.7) 
251 (31.0) 
74 (9.1) 
Alcohol  
   yes 
   no 
   unknown  
 
179 (22.1) 
554 (68.5) 
76 (9.4) 
BMI 
   underweight 
   normal weight 
   overweight 
   unknown 
  
63 (7.8) 
434 (53.6) 
252 (31.1) 
60 (7.4) 
Metastatic sites 
   Liver 
   Peritoneum 
 
337 (41.7) 
83 (10.3) 
Chemotherapy type 
   Never received chemotherapy 
        Adjuvant gemcitabine 
   1st line palliative 
   Gemcitabine 
   FOLFIRINOX 
   Gemcitabine and nab-paclitaxel  
   Other 
 
51 (6.3) 
160 (19.8) 
 
404 (49.9) 
120 (14.8) 
55 (6.8) 
19 (2.3) 
CA19-9 median [IQR] U/ml 519 [76, 3230] 
Abbreviations: BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group 
performance status; IQR, interquartile range. 
 
Table 2. Baseline serum levels of HA and PRO-C3 in patients with PC stratified by stage, presence 
of liver metastases, and ECOG PS compared to patients with other upper gastrointestinal cancer, 
benign diseases, and healthy controls.   
Characteristic  HA median [IQR] 
(ng/mL) 
PRO-C3 median [IQR] 
(ng/mL) 
This article is protected by copyright. All rights reserved.
 
 
Pancreatic cancer (n=809) 
   Stage 
I+II 
III 
IV 
   Liver metastases 
No 
Yes 
  ECOG PS 
0 
1 
2+  
84 [48, 131]a,b 
 
75 [46, 126] 
69 [39, 101] 
94 [51, 140]c 
 
74 [43, 114] 
100 [57, 148]d 
 
76 [44, 121] 
87 [48, 132] 
98 [57, 140]e  
18 [11, 33]a,b 
 
15 [10, 29] 
14 [10, 22] 
20 [13, 41]c  
 
15 [10, 25]  
22 [14, 49]d 
 
17 [11, 35] 
17 [11, 31] 
19 [15, 36]f 
Ampullary carcinoma (n=44) 102 [70, 154] 17 [12, 38] 
Distal biliary tract cancer (n=31) 95 [66, 147] 30 [18, 52] 
Chronic pancreatitis (n=15) 72 [36, 105] 11 [10, 17] 
Intraductal papillary mucinous neoplasm 
(n=41) 
66 [32, 101] 11 [8, 15] 
Duodenal adenoma (n=7) 47 [32, 53] 14 [11, 17] 
No pathologic finding (N=25) 53 [37, 100] 11 [9, 14] 
Healthy controls (n=141 and n=7) 41 [27, 60] 7 [5, 9] 
aP<0.001 compared with healthy controls. 
bP<0.001 compared with benign conditions. 
cP<0.001 across different stages. 
dP<0.001 compared with no liver metastases. 
eP=0.02 across different PS. 
fP<0.05 across different PS. 
Abbreviations: HA, hyaluronan; IQR, interquartile range; PRO-C3, propeptide of type III collagen; 
ECOG PS, Eastern Cooperative Oncology Group performance status. 
 
Table 3. Univariate and multivariate Cox analyses for overall survival according to clinical 
characteristics and pretreatment serum HA and PRO-C3 (HRs are reported per 100 unit increases). 
The significant terms are included in the multivariate analyses.  
 
Univariate analysis Multivariate analysis 
Variable HR (95% CI) P-value HR (95% CI) P-value 
Age ≥ 75 years (vs. <75 years) 1.42 (1.18-1.72) <0.01 1.33 (1.06-1.66) <0.01 
Sex (female vs. male) 1.01 (0.88-1.17) 0.88 - - 
PS 1 (vs. PS 0) 1.60 (1.35-1.89) <0.01  1.34 (1.12-1.61) <0.01 
PS 2 (vs. PS 0) 2.71 (2.15-3.43) <0.01 2.58 (1.99-3.35) <0.01 
BMI (underweight vs. normal weight) 1.27 (0.97-1.66) 0.09 - - 
BMI (overweight vs. normal weight) 1.02 (0.87-1.20) 0.82  - - 
Diabetes (yes vs. no diabetes) 1.14 (0.97-1.34) 0.11 - - 
Smoking ((ever vs. never) 1.08 (0.92-1.26) 0.37   - - 
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Alcohol abuse (ever vs. never)  1.02 (0.86-1.21) 0.84 - - 
Stages 3 and 4 (vs. stage 1 and 2) 3.67 (3.03-4.45) <0.01 3.71 (2.27-6.09) <0.01 
Liver metastasis (yes vs. no met) 2.42 (2.08-2.81) <0.01 1.69 (1.40-2.04) <0.01 
Peritoneum metastasis (yes vs. no met)  1.58 (1.25-1.99) <0.01 1.28 (0.99-1.66) 0.06 
Never received chemotherapy (vs. Res) 3.39 (2.41-4.78) <0.01 4.21 (2.09-8.50) <0.01 
Gemcitabine (P) (vs. Res) 4.24 (3.43-5.26) <0.01 1.05 (0.64-1.72) 0.85 
FOLFIRINOX (P) (vs. Res) 2.48 (1.91-3.22) <0.01 0.64 (0.38-1.09) 0.10 
Gemcitabine+nab-paclitaxel (P) (vs. Res)  2.86 (2.02-4.04) <0.01 0.63 (0.35-1.13) 0.12 
Other combinations (P) (vs. Res) 3.31 (2.03-5.41) <0.01 0.94 (0.49-1.82) 0.86 
CA19-9 ˃median 1.93 (1.65-2.26) <0.01 1.39 (1.17-1.65) <0.01 
HA (per 100 ng/mL) 1.18 (1.13-1.25) <0.01 1.04 (0.97-1.13) 0.27 
PRO-C3 (per 100 ng/mL) 1.28 (1.11-1.49) <0.01 1.42 (1.14-1.76) <0.01 
Abbreviations: BMI, body mass index; PS, performance status; HA 100, additional risk of death for 
every 100-unit increase in hyaluronan; HR, hazard ratio; CI, confidence interval; met, metastasis; P, 
palliative; PRO-C3 100, additional risk of death for every 100-unit increase in pro-peptide of type III 
collagen; Res, resection. 
 
Figure Legends 
Figure 1. Receiver operating characteristic (ROC) curve of baseline serum HA (A, B) and PRO-C3 
(C, D) detection in discriminating PC patients from healthy controls and from patients with benign 
conditions. Abbreviations: AUC, area under the ROC; CI, confidence interval; HA, hyaluronan; 
PRO-C3, propeptide of type III collagen. 
 
Figure 2. Kaplan–Meier survival curves showing the association between pre-treatment serum HA 
(2A) and PRO-C3 (2B) in patients with PC across all stages and for stage 4 (Figures 2C and 2D, HA 
and PRO-C3, respectively). Cut-off is the 75 percentile. 
 
Figure 3. Kaplan–Meier survival curves in patients with PC receiving palliative chemotherapy, 
grouped according to decreased versus increased serum levels of HA and PRO-C3 after the first 
treatment cycle (Figures 3A and 3B) and at the time of first CT evaluation (Figures 3C and 3D). 
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